^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-38877605

    i
    Other names: JNJ-38877605
    Company:
    J&J
    Drug class:
    c-MET inhibitor
    Related drugs:
    30d
    Targeting MET Signalling Activated by CPNE3-RACK1 Interaction Through VWFA Domain to Suppress Lung Cancer Progression. (PubMed, J Cell Mol Med)
    The in vitro and in vivo functions of the MET inhibitor JNJ-38877605 were investigated...CPNE3 could interact with RACK1 through the VWFA domain and activate MET signalling. These findings may provide new insights into the development of novel therapeutic strategies for NSCLC.
    Journal
    |
    RACK1 (Receptor For Activated C Kinase 1)
    |
    JNJ-38877605